Maternal Plasma Hepatocyte Growth Factor Concentrations in Women Who Subsequently Developed Preeclampsia.
- Author:
Shin Young KIM
1
;
So Yeon PARK
;
Mi Jin KIM
;
Moon Young KIM
;
Kyu Hong CHOI
;
Dong Wook KWAK
;
Yoo Jung HAN
;
Hyun Mee RYU
Author Information
- Publication Type:Original Article
- Keywords: Plasma; Hepatocyte growth factor; Risk factor; Subsequent preeclampsia
- MeSH: Amniocentesis; Case-Control Studies; Female; Hepatocyte Growth Factor; Hepatocytes; Humans; Plasma; Pre-Eclampsia; Pregnant Women; Risk Factors
- From:Journal of Genetic Medicine 2012;9(2):78-83
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The aim of this nested case-control study was to investigate the association between hepatocyte growth factor (HGF) concentrations in maternal plasma and the risk of developing preeclampsia. MATERIALS AND METHODS: Plasma HGF concentration were measured in 52 women who subsequently developed preeclampsia and 104 normal pregnant women at the time of genetic amniocentesis (15-20 weeks) by enzyme-linked immunosorbent assay. RESULTS: Maternal plasma HGF concentrations were significantly higher in women with subsequent preeclampsia (median: 737.8 ng/mL vs. 670.4 ng/mL, P=0.003) than in normal controls. However, HGF concentrations were not significantly different between subgroups by preeclamptic complications. After adjusting for potential confounding factors, women with HGF concentrations > or =702.5 ng/mL had a 3.2-fold increased risk (95% CI 2.7-5.4, P<0.001) of subsequent development of preeclampsia compared with women with HGF concentrations <702.5 ng/mL. CONCLUSION: Elevated maternal plasma HGF concentrations in the early second-trimester are associated with an increased risk of developing preeclampsia.
